Author:
Srinivas B. H.,Paul T. Roshni,Uppin Shantveer G.,Uppin Megha S.,Jacob Rachel T.,Raghunadharao D.
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV (2006) BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 60:2049–2055
2. Hasserjian RP, Boecklin F, Parker S, Chase A, Dhar S, Zaiac M et al (2002) STI571 reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J ClinPathol 117:360–367
3. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cerventes F et al (2003) Imatinib compared with interferon, low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994
4. Braziel RM, Launder TM, Druker BJ, Olson SB, Magenis RE, Mauro MJ et al (2002) Hematopathologic and cytogenetic findings in imatinibmesylate-treated chronic myelogenous leukemia patients: 14 months’ experience. Blood 100:435–441
5. Lugli A, Ebnoether M, Coqliatti SB, Gratwohl A, Passweg J, Hess U et al (2005) Proposal of a morphologic bone marrow response score for Imatinibmesylate treatment in chronic myelogenous leukemia. Hum Pathol 36:91–100
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献